MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa1412082

Медицинская библиотека · The New England journal of medicine · 2014

Nivolumab in previously untreated melanoma without BRAF mutation.

Robert Caroline, Long Georgina V, Brady Benjamin, Dutriaux Caroline, Maio Michele, Mortier Laurent, Hassel Jessica C, Rutkowski Piotr, McNeil Catriona, Kalinka-Warzocha Ewa, Savage Kerry J, Hernberg Micaela M, Lebbé Celeste, Charles Julie, Mihalcioiu Catalin, Chiarion-Sileni Vanna, Mauch Cornelia, Cognetti Francesco, Arance Ana, Schmidt Henrik, Schadendorf Dirk, Gogas Helen, Lundgren-Eriksson Lotta, Horak Christine, Sharkey Brian, Waxman Ian M, Atkinson Victoria, Ascierto Paolo A

Клиническое исследование III фазыСравнительное исследованиеСтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

BACKGROUND

Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study.

METHODS

We randomly assigned 418 previously untreated patients who had metastatic melanoma without a BRAF mutation to receive nivolumab (at a dose of 3 mg per kilogram of body weight every 2 weeks and dacarbazine-matched placebo every 3 weeks) or dacarbazine (at a dose of 1000 mg per square meter of body-surface area every 3 weeks and nivolumab-matched placebo every 2 weeks). The primary end point was overall survival.

RESULTS

At 1 year, the overall rate of survival was 72.9% (95% confidence interval [CI], 65.5 to 78.9) in the nivolumab group, as compared with 42.1% (95% CI, 33.0 to 50.9) in the dacarbazine group (hazard ratio for death, 0.42; 99.79% CI, 0.25 to 0.73; P<0.001). The median progression-free survival was 5.1 months in the nivolumab group versus 2.2 months in the dacarbazine group (hazard ratio for death or progression of disease, 0.43; 95% CI, 0.34 to 0.56; P<0.001). The objective response rate was 40.0% (95% CI, 33.3 to 47.0) in the nivolumab group versus 13.9% (95% CI, 9.5 to 19.4) in the dacarbazine group (odds ratio, 4.06; P<0.001). The survival benefit with nivolumab versus dacarbazine was observed across prespecified subgroups, including subgroups defined by status regarding the programmed death ligand 1 (PD-L1). Common adverse events associated with nivolumab included fatigue, pruritus, and nausea. Drug-related adverse events of grade 3 or 4 occurred in 11.7% of the patients treated with nivolumab and 17.6% of those treated with dacarbazine.

CONCLUSIONS

Nivolumab was associated with significant improvements in overall survival and progression-free survival, as compared with dacarbazine, among previously untreated patients who had metastatic melanoma without a BRAF mutation. (Funded by Bristol-Myers Squibb; CheckMate 066 ClinicalTrials.gov number, NCT01721772.).

Для цитирования: Robert Caroline, Long Georgina V, Brady Benjamin, Dutriaux Caroline, Maio Michele, Mortier Laurent, Hassel Jessica C, Rutkowski Piotr, McNeil Catriona, Kalinka-Warzocha Ewa, Savage Kerry J, Hernberg Micaela M, Lebbé Celeste, Charles Julie, Mihalcioiu Catalin, Chiarion-Sileni Vanna, Mauch Cornelia, Cognetti Francesco, Arance Ana, Schmidt Henrik, Schadendorf Dirk, Gogas Helen, Lundgren-Eriksson Lotta, Horak Christine, Sharkey Brian, Waxman Ian M, Atkinson Victoria, Ascierto Paolo A. Nivolumab in previously untreated melanoma without BRAF mutation.. The New England journal of medicine. 2014. DOI: 10.1056/nejmoa1412082.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.